Press Releases

 
Press Releases
  Date Title and Summary View
Jul 18, 2017
CRANBURY, N.J., July 18, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced the closing of its previously announced offering of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an addit...
PDF
Jul 12, 2017
CRANBURY, N.J., July 12, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of therapies for rare and orphan diseases, today announced the pricing of an underwritten offering of 18,367,347 shares of its common stock at $12.25 per share. The gross proceeds from the offering to Amicus are exp...
PDF
Jul 12, 2017
CRANBURY, N.J., July 12, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biopharmaceutical company at the forefront of therapies for rare and orphan diseases, today announced it has commenced a $225 million underwritten public offering of its common stock. J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are acting as joint bo...
PDF
Jul 11, 2017
Data Deemed Sufficient to Support NDA Submission NDA Submission Targeted for 4Q17 Conference Call Today at 8:30am ET CRANBURY, N.J., July 11, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (NASDAQ:FOLD) plans to submit a new drug application (NDA) to the U.S. FDA for the oral precision medicine migalastat for Fabry disease in the four...
PDF
Jun 28, 2017
CRANBURY, N.J., June 28, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, has submitted a Japanese new drug application (J-NDA) to the Pharmaceuticals and Medical Devices Agency (PMDA) to request marketing authorization for migalastat, an oral precision medici...
PDF
Jun 7, 2017
CRANBURY, N.J., June 07, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD) announced today that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate overview and fireside chat at the upcoming Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Thursday, June 15, 201...
PDF
May 31, 2017
Designation Covers Broad Treatment of Epidermolysis Bullosa (EB) Top-Line Phase 3 Data on Track for 3Q17 CRANBURY, N.J., May 31, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD), has received Rare Pediatric Disease designation1 from the U.S. Food and Drug Administration (FDA) for the novel topical medicine SD-101 for the tre...
PDF
May 19, 2017
CRANBURY, N.J., May 19, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD),  has completed the analysis plan for the primary endpoints in the blinded ongoing Phase 3 clinical study (ESSENCE) of the novel topical medicine SD-101 for epidermolysis bullosa (EB). SD-101 was one of the first treatments to receive the FDA's Breakthrough T...
PDF
May 15, 2017
Mean Six-Minute Walk Distance at Month Six Improved in ERT-Naïve Patients (+52 Meters) and ERT-Switch Patients (+38 Meters) Muscle Function Improved in 9 out of 10 Patients Pulmonary Function Improved in a Majority of Patients No Infusion-Associated Reactions Following 200+ Infusions Conference Call at 8:30am ET CRANBURY, N.J., May ...
PDF
May 10, 2017
CRANBURY, N.J., May 10, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company at the forefront of rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present at two upcoming investor conferences: Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas, N...
PDF
Page:
1
... NextLast